ibuprofenum us pharmacia 200 mg apvalkotās tabletes
us pharmacia sp. z o.o., poland - ibuprofēns - apvalkotā tablete - 200 mg
ibuprofenum us pharmacia 400 mg apvalkotās tabletes
us pharmacia sp. z o.o., poland - ibuprofēns - apvalkotā tablete - 400 mg
wintrex 1000 mg/100 mg/12,2 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai
us pharmacia sp. z o.o., poland - paracetamolum, skābes ascorbicum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 1000 mg/100 mg/12,2 mg
dagesil 75 mg/3 ml šķīdums injekcijām/infūzijām
laboratorios basi - industria farmaceutica, s.a., portugal - diklofenaka nātrija sāls - Šķīdums injekcijām/infūzijām - 75 mg/3 ml
neotigason 10 mg cietās kapsulas
teva b.v., netherlands - acitretīns - kapsula, cietā - 10 mg
lopinavir/ritonavir sandoz 200 mg/50 mg apvalkotās tabletes
sandoz d.d., slovenia - lopinavirum, ritonavirum - apvalkotā tablete - 200 mg/50 mg
ascophen p tabletes
vip pharma eesti ou, estonia - skābes acetylsalicylicum, paracetamolum, kofeīns - tablete
lopinavir/ritonavir ranbaxy 100 mg/25 mg apvalkotās tabletes
ranbaxy uk ltd., united kingdom - lopinavirum, ritonavirum - apvalkotās tabletes - 100 mg/25 mg
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcīnas - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.